Article ID: c16-00386
A series of novel quinazoline derivatives have been designed and synthesized, and their inhibitory activities have also been tested against A549 (carcinomic human alveolar basal epithelial cell), MCF-7 (breast cancer) and Hela (cervical cancer cell). Of these compounds, compound 4t showed the most potent inhibitory activity (IC50 = 0.22 μg/mL for Hela, IC50 = 0.15μg/mL for A549 and IC50 = 0.24 μg/mL for MCF-7). Docking simulation had been performed to position compound 4t into the VEGFR active site to determine the probable binding model. These results suggested that compound 4t with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent.
